Tocilizumab in Hospitalized Patients with Severe COVID-19: An Open Label, Prospective Study

Karampitsakos, Theodoros; Malakounidou, Elli; Papaioannou, Ourania; Dimakopoulou, Vasilina; Zarkadi, Eirini; Katsaras, Matthaios; Tsiri, Panagiota; Tsirikos, Georgios; Georgiopoulou, Vasiliki V.; Oikonomou, Ioanna; Davoulos, Christos; Velissaris, Dimitrios; Sampsonas, Fotios; Marangos, Markos; Akinosoglou, Karolina; Τzouvelekis, Αrgyris

doi:10.21203/rs.3.rs-824171/v1

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global impact of the ongoing coronavirus disease 2019 (COVID- 19) pandemic has been unparalleled. The disease course is variable, manifesting from asymptomatic to fatal forms, and longterm complications could have further devastating effects (1)(2)(3). Emerging evidence indicate that a substantial proportion of infected individuals may experience prolonged symptoms lasting for more than 6 months (4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model

et al. 2023

View full text Add to dashboard Cite

IntroductionPost-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD).MethodsIn this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1.ResultsTwo hundred thirty-two (n = 232) patients were analyzed. FVC% predicted was ≥80, between 60 and 79 and <60 in 74.2% (n = 172), 21.1% (n = 49), and 4.7% (n = 11) of the cohort, respectively. DLCO% predicted was ≥80, between 60 and 79 and <60 in 69.4% (n = 161), 15.5% (n = 36), and 15.1% (n = 35), respectively. Extent of ground glass opacities was ≥30% in 4.3% of patients (n = 10), between 5 and 29% in 48.7% of patients (n = 113) and <5% in 47.0% of patients (n = 109). The extent of reticulation was ≥30%, 5–29% and <5% in 1.3% (n = 3), 24.1% (n = 56), and 74.6% (n = 173) of the cohort, respectively. Patients (n = 13, 5.6%) with fibrotic lung disease and persistent functional impairment at the 6-month follow-up received antifibrotics and presented with an absolute change of +10.3 (p = 0.01) and +14.6 (p = 0.01) in FVC% predicted at 3 and 6 months after the initiation of antifibrotic.ConclusionPost-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are “immature.” Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches.

show abstract